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Abstract
Methyl CpG binding protein 2 (MeCP2) binds DNA, and has a preference for methylated CpGs and, hence, in cells, it
accumulates in heterochromatin. Even though it is expressed ubiquitously MeCP2 is particularly important during neuronal
maturation. This is underscored by the fact that in Rett syndrome, a neurological disease, 80% of patients carry a mutation in
the MECP2 gene. Since the MECP2 gene lies on the X chromosome and is subjected to X chromosome inactivation, affected
patients are usually chimeric for wild type andmutant MeCP2. Here, we present the generation and characterization of the first
rat monoclonal MeCP2 specific antibodies as well as mouse monoclonal antibodies and a rabbit polyclonal antibody. We
demonstrate that our antibodies are suitable for immunoblotting, (chromatin) immunoprecipitation and immunofluorescence
of endogenous and ectopically expressed MeCP2. Epitope mapping revealed that most of the MeCP2 monoclonal antibodies
recognize the C-terminal domain and one the N-terminal domain of MeCP2. Using slot blot analysis, we determined a high
sensitivity of all antibodies, detecting amounts as low as 1 ng of MeCP2 protein. Moreover, the antibodies recognize MeCP2
from different species, including human, mouse, rat and pig. Lastly, we have validated their use by analyzing and quantifying X
chromosome inactivation skewing using brain tissue of MeCP2 heterozygous null female mice. The new MeCP2 specific
monoclonal antibodies described here perform well in a large variety of immunological applications making them a very
valuable set of tools for studies of MeCP2 pathophysiology in situ and in vitro.
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Introduction
Methyl CpG binding protein 2 (MeCP2) was the second methyl
CpG binding protein to be discovered [1] and the first to be cloned
[2]. In interphase mouse nuclei, MeCP2 is prominently localized
at heterochromatic foci [2]. In metaphase chromosomes, the
association of MeCP2 with euchromatic arms is rather weak
compared to a strong localization at pericentric heterochromatin
[2], highly enriched in heavily methylated major satellite DNA
repeats [3]. MeCP2 consists of a conserved methyl CpG binding
domain (MBD) that binds to 5-methyl cytosine with high affinity
and is shared with the other MBD protein family members. The
transcriptional repression domain (TRD), which carries a nuclear
localization sequence interacts with histone deacetylases and the
transcriptional corepressor Sin3A [4,5,6]. Finally, the C-terminal
domain binds nucleosomes (Figure 1).
Even though MeCP2 is ubiquitously expressed, it is genetically
linked to a neurological disease called Rett syndrome (RTT, OMIM
312750). RTT was first described in 1966 by Andreas Rett [7] and
affects one in every 10,000–15,000 female births [8,9,10]. Affected
girls seem to develop normally until six to 18 months, subsequently
they enter a developmental arrest, which is followed by strongly
impaired motor skills, stereotypic hand movements, loss of speech,
seizures, abnormal breathing, microcephaly, ataxia and other
symptoms. Mutations within the MECP2 gene located on
chromosome Xq28 are found in approximately 80% of all classic
RTT cases [8,11]. SinceMECP2 is located on the X chromosome it
is subjected to random X chromosome inactivation. Thus,
depending on which chromosome was inactivated, a mosaic pattern
of healthy (wild type allele expressing) and affected (mutant allele
expressing) cells is created [12]. A further important aspect is the
stark discrepancy between MeCP2 mRNA expression levels
compared to protein levels (e.g. [13]), which highlights the need
for highly specific antibodies detecting MeCP2 on a protein level.
Up to now rabbit polyclonal and mouse monoclonal antibodies
have been raised against MeCP2 but the available antibodies are
PLoS ONE | www.plosone.org 1 November 2011 | Volume 6 | Issue 11 | e26499
limited in their application range. Here, we describe the
generation of the first rat monoclonal antibodies against MeCP2
being capable of reacting specifically in most common immuno-
logical applications. To complete the collection, we generated two
mouse monoclonal antibodies and a rabbit polyclonal antibody.
We could demonstrate the suitability of these high affinity and
specific antibodies for immunoblotting, (chromatin) immunopre-
cipitation, and immunofluorescence stainings of cells and tissues.
Additionally, we used one of our anti-MeCP2 rat monoclonal
antibodies on MeCP2 heterozygous null mouse brain to analyze
and quantify X chromosome inactivation skewing.
Materials and Methods
Plasmids
Mammalian expression constructs (Figure 3 and S1A) coding
for GFP or YFP-tagged rat MeCP2 full length (MeCP2G) and
domain constructs (MeCP2Y.3 and MeCP2Y.5) were previously
described [14,15]. The mammalian expression constructs
MeCP2G.9 and MeCP2G.8 were generated from the above
plasmids by PCR amplification using the following primers:
pMeCP2G.9 ss ccgctcgaggccatggggagcccttccaggagagaaca
as cgcggatccttccgggtcttgcgcttcttgatggggagcac
pMeCP2G.8 ss ggaagatctgccatggaaaccgtcagcattgaggtcaag
as ataagaatgcggccgcttacttgtacagctcgtccatgcc
The mammalian expression construct (Figure 6 and S1B)
expressing GFP-tagged human MECP2 was described before [16]
and was provided by S. Kudo (Hokkaido Institute of Public
Health, Sapporo, Japan). For expression in Sf9 (Invitrogen Paisley
PA4 9RF, UK) insect cells the Bac-to-Bac baculovirus expression
system (Invitrogen Paisley PA4 9RF, UK) was used. To express
MeCP2 with a N-terminal double strep-tag (Figure 1), a sequence
encoding the strep-tactin target peptide strep tag III
(MWSHPQFEKGGGSTGGGSGGGSWSHPQFEK) was syn-
thesized (Entelechon, Bad Abbach, Germany) flanked by BamHI
and NotI sites and subcloned into pFastBac1 (Invitrogen, Paisley
PA4 9RF, UK) using the same sites. Rat MeCP2 full length was
generated by PCR amplification from MeCP2G (described above)
using the following primers:
MeCP2 ss: ggaagatctgccatggaaaccgtcagcattgaggtcaag
as: ataagaatgcggccgcttacttgtacagctcgtccatgcc
with NotI and XhoI sites and subcloned in frame with the strep-
tag in the pFastBac1 vector. For expression of rat MeCP2-GFP in
Sf9 insect cells (Figure 2) the mammalian expression construct
Figure 2. Antibody sensitivity. The detection limit of the MeCP2 antibodies was tested on native rat MeCP2-GFP by slot blotting analysis and lies
between 1.58 and 0.78 ng of recombinant purified rat MeCP2.
doi:10.1371/journal.pone.0026499.g002
Figure 1. Antigen preparation. Purified strep-tagged MeCP2 (rat)
and purified intein tagged MECP2 (human) were subjected to a SDS-
PAGE and stained with Coomassie. The molecular weight markers are
labeled in the middle. A schematic representation of the rat MeCP2
protein and its functional domains is shown below. MBD: methyl CpG
binding domain; TRD: transcriptional repression domain; NLS: nuclear
localization signal.
doi:10.1371/journal.pone.0026499.g001
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coding for MeCP2G full length (described above) was cut using
NotI and XhoI and cloned in frame in the pFastBac1 vector.
A prokaryotic expression construct coding for intein tagged
human MECP2 (Figure 1) [17] was obtained from C.L. Woodcock
(University of Massachusetts, Amherst, USA).
Tissues
Male mouse MeCP2 hemizygous brains (Figures 5 and 6) [18]
were kindly provided by the group of P. Huppke (Georg August
University, Go¨ttingen, Germany). Female mouse MeCP2 null
heterozygous brains (Figure 7) [18] were kindly provided by the
group of L. Villard (Faculte de Medecine La Timone, Marseille,
France). Wild type mouse brains (C57BL/6N; Charles River
Laboratories International, Inc., Wilmington, MA 01887, USA)
were used as control. Mice were over 10 months old.
Cell culture and transfection
For immunofluorescence (IF) experiments mouse C2C12
myoblasts [19] were cultured using standard conditions described
previously [20]. For subsequent IF experiments (Figure 6 and
S1B), C2C12 cells were transiently transfected with human GFP-
MECP2 expression construct [16] using Transfectin (Bio Rad,
Mu¨nchen, Germany) according to manufacturer’s advice.
For the epitope mapping (Figure 3 and S1A), human embryonic
kidney (HEK) 293T [21] cells were cultured in DMEM
supplemented with 10% fetal calf serum and 50 mg/ml gentamicin
and transfected with full length rat MeCP2 and domain constructs
(described above) using polyethylenimine (Sigma, St. Louis, MO,
USA).
MeCP2 antigens for immunization (Figure 1) and slot blot
applications (Figure 2) were produced using the baculovirus system
in Sf9 insect cells. Sf9 cells were maintained in EX-CELL 420
Insect Serum Free (SAFC) medium supplemented with 10% fetal
bovine serum shaking at 100 rpm and 28uC. Transfection of Sf9
cells to produce recombinant baculovirus, was performed using
Cellfectin (Invitrogen, Paisley PA4 9RF, UK) according to the
manufacturer’s instructions.
Antigen purification
Sf9 insect cells were infected with the recombinant baculovirus
(coding for MeCP2 with N-terminal double strep-tag; [22]) and
incubated at 28uC with shaking for 5 days. The cells were pelleted
by centrifugation (2006 g, 5 min, 4uC) and resuspended in a
buffer containing 25 mM Tris-HCl, pH 8.0; 1 M NaCl; 50 mM
glucose; 10 mM EDTA; 0.2% Tween-20; 0.2% NP40. The buffer
was supplemented with protease inhibitors (Complete mini;
Roche, Mannheim, Germany). After incubation on ice for
10 min, cells were disrupted with a high-pressure homogenizer
(EmulsiFlex-C5, Avestin) followed by centrifugation at 14,0006 g
for 30 min.
Strep-tagged recombinant rat MeCP2 protein was purified by
incubating the supernatant with 500 ml of strep-tactin sepharose
beads (IBA, Go¨ttingen, Germany) for 4 h at 4uC on a rotary
shaker. To elute strep-tagged proteins, the beads were incubated
with D-Desthiobiotin (0.5 mg/ml; IBA, Go¨ttingen, Germany),
dissolved in 16 PBS, for 30 min at 4uC. After centrifugation
(2006g, 2 min), beads were separated from the eluate containing
the purified proteins. The elution step was performed three
successive times.
Intein tagged human MECP2 protein was purified as previously
described resulting in untagged MECP2 through protein splicing
[23].
Immunizations, generation of hybridomas and ELISA
screening
Monoclonal antibodies specific for MeCP2 were generated via
the hybridoma technology as described by Rottach et al. [24].
80 mg of a N-terminal, strep-tagged full length rat MeCP2 were
Figure 3. Epitope mapping. To determine the binding site of the new monoclonal antibodies within the MeCP2 protein, we probed extracts of
mammalian cells expressing different MeCP2 constructs fused to GFP/YFP as indicated. To control for the level of the fusion proteins, the membranes
were reprobed with anti GFP mouse monoclonal antibody. A summary of the epitope mapping results for the different antibodies is shown below.
MeCP2 functional domains are as in Figure 1.
doi:10.1371/journal.pone.0026499.g003
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Figure 4. Antibody specificity. A) Sequence alignment of MeCP2 from different species. Identical residues are shaded in gray. The identities range
from 93% (human-mouse) to 97% (rat-mouse). B) For a multi-species immunoblot nuclear extracts from pig, mouse and rat brain (106 nuclei) were
loaded and probed with the antibodies as indicated. C) For immunoprecipitation analysis, mouse brain whole cell (for rat antibodies) and nuclei (for
mouse antibodies) extracts were incubated with the monoclonal antibodies as indicated followed by western blot analysis.
doi:10.1371/journal.pone.0026499.g004
Figure 5. Chromatin immunoprecipitation. Chromatin immunoprecipitation assays were performed using mouse brain nuclear extracts
obtained from wild type mice and MeCP2 knock out (KO) mice as negative control. The anti histone H3 antibody was used as a positive control of
chromatin immunoprecipitation assay efficiency. IgG was used as a negative control of chromatin immunoprecipitation.
doi:10.1371/journal.pone.0026499.g005
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injected both intraperitoneally and subcutaneously into Lou/C
rats and CBL mice using CpG2006 (TIB MOLBIOL, Berlin,
Germany) as adjuvant. 8 weeks later and 3 days before fusion a
boost was given intraperitoneally and subcutaneously. Spleen cells
were isolated and fused to the myeloma cell line P3X63-Ag8.653
(ATCC, Rockville, MD, USA) using polyethylene glycol 1500
(PEG 1500, Roche, Mannheim, Germany). After fusion, cells were
cultured in 96-well plates using RPMI 1640 with 20% fetal calf
serum, penicillin/streptomycin, glutamine, pyruvate, and non-
essential amino acids (PAA, Co¨lbe, Germany) supplemented by
aminopterin (Sigma, St. Louis, MO, USA). The hybridoma
supernatants were tested in a solid-phase enzyme linked
immunosorbent assay (ELISA). Microtiter plates were coated over
night with strep-tagged rat MeCP2 at a concentration of 3–5 g/ml
in 0.1 M sodium carbonate buffer (pH 9.6) and blocked with non-
fat milk (Frema, Neuform, Zarrentin, Germany). The hybridoma
supernatants were added and the bound monoclonal antibodies
were detected using a cocktail of biotinylated mouse monoclonal
antibodies against the rat IgG heavy chains, thus avoiding the
detection of IgM mouse monoclonal antibodies (anti IgG1, anti
IgG2a, anti IgG2b [ATCC, Manassas, VA], anti IgG2c
[Ascenion, Munich, Germany]). For visualization, peroxidase-
labeled avidin (Alexis, San Diego, CA) antibodies were applied
and o-phenylenediamine was used as chromogen in the peroxidase
reaction. The clones 4H7, 4G10 and 4E1 (rat monoclonal) as well
as 4B4 and 8D11 (mouse monoclonal) were stably subcloned and
used for further characterization.
The rabbit polyclonal antibody was generated using the
untagged human MECP2 according to the Express rabbit protocol
from PickCell (PickCell, Amsterdam, Netherlands) and used in
form of antiserum.
All monoclonal antibodies are available upon request.
Ethics statement
Immunizations of mice and rats for the purpose of generating
monoclonal antibodies were approved by the Government of
Upper Bavaria, according to the animal experimentation law 1 8a,
permit number 209.1/211-2531.6-4/99.
Sensitivity assay via slot blot analysis
Purification of MeCP2-GFP. Sf9 insect cells were infected
with the recombinant baculovirus (coding for rat MeCP2-GFP)
and incubated at 28uC with shaking for 5 days. The cells were
pelleted and resuspended as explained above for strep-tag MeCP2
and disrupted by sonication (three times each for 25 seconds, 70%
power; Bandelin Sonopuls GM70, Sonontrode HD70, Berlin,
Germany) on ice. Lysates were cleared by centrifugation at
15,0006 g for 30 min at 4uC.
Recombinant rat MeCP2-GFP protein was purified by
incubating 200 ml whole cell lysate with 1 ml (1.5 mg/ml) GBP
nanotrap according to the manufacturer’s advice (Chromotek,
Planegg-Martinsried, Germany). After transfer of the GBP nano-
trap beads containing lysate to a Bio-Rad Poly-Prep chromatog-
raphy column (Cat: 731-1550, Bio-Rad Laboratories, Hercules
CA 94547, USA) the column was washed three times with 10 ml
PBS. To elute the MeCP2-GFP protein, the beads were incubated
with 5 ml of a high salt buffer. Buffer exchange was done with PBS
using Amicon ultra centrifugal filters (Ultracel 10 kDa molecular
weight cutoff; Millipore, Ireland). Eluted protein was quantified
with Pierce the 660 nm protein assay (Thermo Scientific; Pro:
#1861426, Schwerte, Germany) and checked by SDS-PAGE
analysis (data not shown).
Slot blotting analysis. Native MeCP2-GFP was spotted
directly onto a nitrocellulose membrane (GE Healthcare,
Mu¨nchen, Germany). Membranes were incubated in blocking
buffer, 5% (w/v) non-fat dry milk in PBS (PBSM), for 20 min at
room temperature. Primary antibodies were used undiluted and
incubated for 2 h at room temperature, followed by three washes
in PBS/0.1% Tween-20. Subsequently, membranes were
incubated for 1 h at room temperature with horseradish
peroxidase conjugated anti-rabbit IgG (Sigma, St. Louis, MO,
USA) diluted 1:10,000 or anti-mouse (GE Healthcare, Mu¨nchen,
Germany) and rat IgG (Sigma, St. Louis, MO, USA) 1:5,000 in
5% (w/v) PBSM. After three washing steps in PBS/0.1% Tween-
20, signals were detected with ECL (GE Healthcare, Mu¨nchen,
Germany).
Epitope mapping
For epitope mapping, different constructs of rat MeCP2 with C-
terminal GFP or YFP tag were used for transient transfection of
HEK 293T cells. After cell lysis (20 mM Tris-HCl pH 7.5,
150 mM NaCl, 0.5%NP40, 2 mM PMSF, 0.5 mM EDTA, 16
mammalian protease inhibitor mix, 1 mg/ml DNase, 2 mM
MgCl2) the concentration of the GFP fusion proteins was
calculated using a fluorescent read out of GFP and YFP (InfiniteH
M1000, TECAN), respectively (GFP: excitation wavelength:
490 nm, emission wavelength: 511 nm, YFP: excitation wave-
length: 525 nm, emission wavelength: 538 nm). The protein
concentration was normalized to the construct with the lowest
expression rate and lysates were diluted accordingly (228 nM GFP
or YFP). The samples were boiled in Laemmli sample buffer at
95uC for 10 min and loaded on a 10% SDS-PAGE. Western blot
analysis was performed as described above. In addition to the
polyclonal and monoclonal anti MeCP2 antibodies, anti GFP
mouse monoclonal antibody (Cat: 11814460001, Roche Diagnos-
tics GmbH, Mannheim, Germany) was used to control for
expression level of the different deletion proteins.
Cross-species reactivity assay via western blot analysis
For western blot analysis brain cell nuclei were extracted from
pig (obtained fresh from the local slaughterhouse), mouse and rat
(Charles River Laboratories International, Inc., Wilmington, MA
01887, USA) as described [25] and lysed in RIPA buffer (50 mM
Tris/HCl pH 8, 150 mM NaCl, 1% Tween, 0.5% Doc, 0.1%
SDS). For each gel lane, lysates from 106 nuclei were loaded.
Figure 6. In situ analysis of MeCP2 in cells and tissue. A) Mouse myoblasts (C2C12 cells) were transiently transfected with GFP-MECP2 (human)
and fixed using formaldehyde. MeCP2 was then detected with our monoclonal antibodies (undiluted) and our rabbit polyclonal antibody (1:500). The
first row shows the DNA counterstain (DAPI) of transfected and untransfected cells (green). The row underneath shows the signal obtained by our
antibody staining (red). The third row shows the localization of the transfected GFP-MECP2 (blue). The merge contains an overlay of the antibody
staining, the fluorescent signal of GFP-MECP2 and the DNA counterstain. Scale bar 20 mm. B) Mouse wild type brain sections (25 mm) were stained
using our antibodies. The first row shows the DNA counterstain with DAPI highlighting heterochromatic regions. The central row shows the signal
obtained by immunofluorescence with our antibodies. The last row shows an overlay of DAPI and MeCP2. Scale bar 20 mm. C) Mouse MeCP2
hemizygous null brain sections (25 mm) were stained as described above as a negative control. Mouse anti B23 antibody was used as a positive
control (consecutive section when testing mouse monoclonal anti MeCP2). Scale bar 40 mm.
doi:10.1371/journal.pone.0026499.g006
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Samples were separated on a 10% SDS-PAGE and transferred
to a nitrocellulose membrane (GE Healthcare, Mu¨nchen,
Germany). The following primary antibodies were used for
western blot analysis: rabbit polyclonal anti MeCP2 (1:500),
mouse monoclonal and rat monoclonal anti MeCP2 (undiluted).
Secondary antibodies were as above for slot blot analysis.
Immunoprecipitation
Mechanically disrupted mouse brain tissue (3–4 brains) was
dissolved in buffer A (20 mM Tris pH 7.9, 0.6 M NaCl, 1.5 mM
MgCl2, 0.2 mM EDTA, 0.4% NP-40), and then diluted with
buffer B (20 mM Tris pH 7.9, 1.5 mM MgCl2, 0.2 mM EDTA,
0.4% NP-40) to obtain an NaCl concentration of 200 mM. Mouse
brain extracts were incubated with 400 ml of the rat monoclonal
MeCP2 antibody indicated, at 4uC for 2 h with shaking. As
negative control, anti RFP mix rat monoclonal antibody [26] of
equal amount was used. 100 ml protein G agarose beads, that were
equilibrated with buffer B, were added and incubated with the
extract for 1 h at 4uC with shaking. After three washes with buffer
B immuno complexes were dissolved in 60 ml 16Laemmli sample
buffer.
For successful immunoprecipitation using the mouse monoclo-
nal antibodies nuclei had to be isolated first, followed by a
modified protocol. Mechanically disrupted mouse brain tissue was
resuspended and washed with ice-cold PBS supplemented with
protease inhibitor cocktail (Roche, Mannheim, Germany). Cell
pellets were resuspended in cell lysis buffer (HEPES 5 mM, KCl
85 mM, NP40 0.5% pH 8.0) supplemented with protease
inhibitor cocktail and subsequently homogenized with a douncer.
The nuclear pellet obtained was resuspended in nuclei lysis buffer
(Tris-HCl 50 mM, EDTA 10 mM, SDS 1% pH 8.1) and
sonicated with a Bioruptor (Diagenode) for 5 minutes (30 sec
ON, 30 sec OFF cycles) to get a homogeneous extract.
The extract was diluted with immunoprecipitation buffer (SDS
0.1%, Triton X-100 1.1%, EDTA 1.2 mM, NaCl 165 mM, Tris-
HCl 16.7 mM pH 8.1) and followed by a pre-clearing overnight
at 4uC with magnetic beads (Invitrogen, Paisley PA4 9RF, UK).
Non-related mouse IgG antibody was used as a negative control.
The amount of extract that was used for each immunoprecip-
itation varied from 10–500 mg. Antibody-Dynabeads M-280
sheep anti-mouse IgG (Invitrogen, Paisley PA4 9RF, UK) were
added to pre-cleared chromatin and incubated with shaking for
2 h at 4uC. 10 mg of nuclear extract were loaded as input. After
three washes with immunoprecipitation buffer immuno complex-
es were eluted from the beads with 25 ml 26 Laemmli sample
buffer.
Samples were analyzed by western blot as described above.
Chromatin immunoprecipitation
Nuclei were obtained from wild type and MeCP2 knock out
male brain as described above with an additional cross-linking
step, after mechanical disruption, with 1% formaldehyde for
10 min. Adding glycine to a final concentration of 0.125 M
stopped the cross-linking reaction. The lysed nuclear pellet was
sonicated with a Bioruptor (Diagenode) for 15 minutes (30 sec
ON, 30 sec OFF cycles). The average chromatin size of the
fragments obtained was ,300 bp. Magnetic beads were used for
pre-clearing of diluted chromatin (over night at 4uC) and for
incubation (2 h at 4uC with shaking) with H3 (ab1791, Abcam),
our rat monoclonal antibodies: 4E1, 4H7, and 4G10 or our
mouse monoclonal antibodies: 4B4 and 8D11. Non-related
mouse IgG antibody was used as a negative control. The input
was obtained from the nuclear extract and represents 5% of the
chromatin that is used for the chromatin immunoprecipitation
with each antibody. The immuno-complexes were washed: twice
with low salt buffer (Tris-HCl 50 mM pH 8.0, NaCl 150 mM,
SDS 0.1%, NP-40 1%, EDTA 1 mM, deoxicolate Na 0.5%),
twice with high salt buffer (Tris-HCl 50 mM pH 8.0, NaCl
500 mM, SDS 0.1%, NP-40 1%, EDTA 1 mM, Na deoxicolate
0.5%), twice with LiCl buffer (Tris-HCl 50 mM pH 8.0, LiCl
250 mM, SDS 0.1%, NP-40 1%, EDTA 1 mM, Na deoxicolate
0.5%) and twice with TE buffer (Tris-HCl 10 mM pH 8.0,
EDTA 0.25 mM). Cross-linked chromatin was then eluted from
the magnetic beads (Dynabeads M-280 sheep anti-mouse IgG for
mouse monoclonal antibodies and protein G for rat monoclonal
antibodies) by adding elution buffer (NaHCO3 100 mM, SDS
1%). Samples were reverse cross-linked over night at 65uC and
incubated with proteinase K at 50 mg/ml final concentration for
1 h. DNA was purified with the PCR purification kit (Qiagen)
and used for PCR analysis, which was carried out with the
following primers:
Xist (promoter) 59-CCTGTACGACCTAAATGTCC-39
59-GTATTAGTGTGCGGTGTTGC-39.
In the case of our rat monoclonal antibodies 38 PCR cycles
were used and in the case of our mouse monoclonal antibodies 35
cycles.
Immunofluorescence analysis
Cells. For immunofluorescence staining, C2C12 cells were
seeded on glass coverslips and transiently transfected with GFP
tagged MECP2 (human). Cells were fixed with 3.7%
formaldehyde in PBS and incubated with the undiluted rat/
mouse anti MeCP2 antibodies for 1 h at room temperature. After
incubation with the secondary Alexa 647 conjugated goat anti rat/
mouse IgG antibody (Invitrogen Paisley PA4 9RF, UK) diluted
1:400 in PBS containing 2% BSA, the cells were counterstained
with DAPI (2 mg/ml) and mounted in Vectashield medium
(Vector Labs, Burlingame, CA, USA).
Tissues. Mouse brains were fixed by overnight immersion in
PBS-buffered 4% paraformaldehyde. The brains were embedded
in Tissue Tek (Sakura, Zoeterwoude, Netherlands) and
cryosectioned (25 mm) using a cryostat HM 560 (Microm,
Walldorf, Germany).
Sections were air dried at room temperature for 30 min, re-
hydrated in 10 mM sodium citrate buffer (pH 6.0) for 5 min,
pulse-heated (80uC) for 30 min in the microwave. The slides were
equilibrated in PBS after heating and incubated with the following
antibodies: anti MeCP2 mouse monoclonal (undiluted), rat
monoclonal (undiluted), rabbit polyclonal (1:500), anti B23 mouse
monoclonal (Sigma, St. Louis, MO, USA, 1:1,000) and anti
tyrosine hydroxylase rabbit antibody (AB152, Millipore, Billerica,
MA, USA) Both, primary and secondary antibodies were
complemented with 0.1% Triton X-100 and 1% BSA. No
additional blocking step was performed. Incubation was done
under a glass chamber (made of coverslips) in a humid box for 12–
24 h at room temperature [27]. Washings between antibody
incubations and after incubation with secondary antibodies were
performed with PBS with 0.05% Triton X-100 at 37uC,
3620 min. In order to stabilize preparations, immunostained
sections were post-fixed with 2% paraformaldehyde for 10 min
before counterstaining with DAPI (2 mg/ml) for 1 h and mounted
in Vectashield medium (Vector Labs, Burlingame, CA, USA).
Microscopy
Epifluorescence images were obtained on a Zeiss Axiovert 200
microscope equipped with Plan-Apochromat 663/1.4 numerical
aperture (NA) oil immersion objective lenses and a Sensicam
(PCO) CCD camera. Confocal images were collected using an
Novel MeCP2 Specific Monoclonal Antibodies
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UltraVIEW VoX spinning disc system (Perkin Elmer) on a Nikon
Ti microscope equipped with an oil immersion Plan-Apochromat
640/1.3 NA objective lens (pixel size in XY=186 nm, Z-
step = 0.3 mm).
Scoring of tyrosine hydroxylase and MeCP2 positive cells was
done by eye in z-stacks.
Results and Discussion
Generation of rat/mouse monoclonal antibodies against
MeCP2
To generate new rat and mouse antibodies potentially detecting
different domains of MeCP2, we generated a baculovirus
expression plasmid coding for the full length rat MeCP2 with a
double strep-tag and transfected/infected Sf9 insect cells with this
construct. The recombinant protein was purified using strep-tactin
sepharose leading to a single band in SDS-PAGE analysis
(Figure 1). The protein was used to immunize Lou/C rats and
CBL mice, leading to the generation of a panel of clonal
hybridomas by fusion of lymphocytes from immunized animals
with the myeloma cell line P3X63-Ag8.653. All antibodies
generated by the hybridomas were initially screened in a solid-
phase enzyme linked immunosorbent assay (ELISA, data not
shown). Positive hybridoma supernatants from clones 4H7, 4G10
and 4E1 (rat monoclonal) as well as 4B4 and 8D11 (mouse
monoclonal) were stably subcloned and used for further charac-
terization. In parallel, we immunized rabbits with untagged
human MECP2 protein to generate polyclonal antibodies and
used the resulting antiserum directly.
Sensitivity of the rat and mouse antibodies
To test the sensitivity of the antibodies we performed slot blot
analysis with native rat MeCP2-GFP protein. The protein was
applied in decreasing amounts ranging from 25 ng down to
0.78 ng. All monoclonal antibodies showed clear signals down to
1.56 ng of native protein and the rat monoclonal antibody 4E1
was still able to detect 0.78 ng of MeCP2 protein (Figure 2). The
rabbit anti MeCP2 polyclonal antiserum was also able to detect
down to 0.78 ng of native protein (Figure 2). The last column
contained 500 ng BSA as negative control and none of the
antibodies reacted with it.
Epitope mapping
To determine the binding domain of the new monoclonal
antibodies within the MeCP2 protein, we used different constructs
of GFP/YFP tagged MeCP2 expressed in mammalian cells. The
cell lysates were analyzed by SDS-PAGE, blotted on a
nitrocellulose membrane and incubated with the different
antibodies. All fusions were expressed as controlled by incubation
of the membranes with anti GFP mouse monoclonal antibody.
The results (Figure 3 and S1A) show that the rat monoclonal
antibodies 4G10 and 4H7 reacted against the C-terminus of
MeCP2 and 4E1 against the N-terminus. Both mouse monoclonal
antibodies 4B4 and 8D11 showed specific binding to the C-
terminus. Since none of the antibodies detected the MBD domain,
which is highly conserved in all MBD proteins no cross-reaction
with these proteins is expected. Additionally, the polyclonal rabbit
antibody detected all fragments except the TRD.
Specificity and cross species reactivity
MeCP2 is highly conserved throughout different species
(Figure 4A). To test for cross species reactivity, nuclei from pig,
mouse and rat brain tissue were isolated and extracts analyzed by
western blot. As shown in Figure 4B all antibodies detected
endogenous MeCP2 in mouse and rat. Remarkably, the rat
monoclonal antibody 4E1 was the only one that did not detect
MeCP2 in nuclear extracts from pig brain. This coincides with the
fact that it is the only antibody in our tests to react with the N-
terminal part (amino acids 1–78) of MeCP2 (see below). Only five
amino acids are not identical in this domain of MeCP2 in the pig
compared to mouse and rat. We, thus, conclude that the epitope
recognized by rat monoclonal antibody 4E1 must include one or
more of these residues (Figure 4A, highlighted in red).
An important and commonly used method for studying protein
interaction partners is immunoprecipitation. Thus, we tested next
the ability of the monoclonal antibodies to specifically immuno-
precipitate MeCP2 from mouse brains. We could show that our
three rat antibodies were able to specifically pull down MeCP2
from whole brain extract (Figure 4C). Additional unspecific bands
at 35 kDa were also detected in the negative control (rat anti RFP
antibody mix) [26] and are most probably due to unspecific
binding to the beads (data not shown). To successfully use our two
mouse monoclonal antibodies for immunoprecipitation we needed
to isolate nuclei from mouse brain first. We could then show that
our mouse antibodies were also capable of specifically pulling
down MeCP2 from mouse brain nuclei extracts (Figure 4C).
To next determine if our monoclonal MeCP2 antibodies are
competent for chromatin immunoprecipitation analysis using
purified nuclei from mouse brain. We analyzed the occupancy of
MeCP2 in the promoter of Xist in the X chromosome, which is
known to bind MeCP2 in mouse and is used as a standard
positive control for MeCP2 binding. Two of our rat monoclonal
antibodies were able to immunoprecipitate chromatin (4E1 and
4H7, Figure 5) with 4H7 producing a stronger signal than 4E1
and 4G10 not yielding a detectable signal. The latter might be
due to technical limitations, or to the epitope recognized by the
4G10 mAb being masked when the MeCP2 protein is bound to
chromatin. From our mouse antibodies only 4B4 was able to
clearly chromatin immunoprecipitation (Figure 5). The three
antibodies (rat 4E1 and 4H7 and mouse 4B4) suitable for
chromatin immunoprecipitation show no band in the knockout
brain whereas H3, which is used as positive control for
chromatin immunoprecipitation, shows a band in wild type
and knock out brain. Our polyclonal rabbit anti MeCP2
antibody was previously shown to be suitable for chromatin
immunoprecipitation analysis [28]. Our antibodies therefore
cover the whole range of important biochemical assays
commonly performed.
In situ analysis of MeCP2 in cells and in tissue
Western blot techniques usually deal with denatured protein
and do not give information about the localization of the protein in
the cell. It is therefore important to test whether the new
antibodies correctly detect MeCP2 localization in situ. MeCP2 is
predominantly localized at pericentric heterochromatic regions in
mouse cells, which are highly enriched in strongly methylated
major satellite DNA repeats and tend to form clusters known as
chromocenters [14]. Immunostainings were thus performed on
mouse myoblasts expressing GFP tagged human MECP2 using
formaldehyde and methanol as fixation reagents (Figure 6A and
S1B). Our three rat monoclonal antibodies revealed strong signals
co-localizing with the ectopically expressed GFP-MECP2 and
worked in both fixation conditions. Untransfected cells did not
give a signal, consistent with undetectable endogenous levels of
MeCP2 in those cells [14]. Using the mouse monoclonals, only
4B4 gave a signal for ectopically expressed protein. 8D11
exhibited high background noise and no specific binding in both
fixation conditions. Our polyclonal rabbit antiserum showed
Novel MeCP2 Specific Monoclonal Antibodies
PLoS ONE | www.plosone.org 8 November 2011 | Volume 6 | Issue 11 | e26499
strong and specific binding even when used at a dilution of 1:500.
DAPI was used as a counterstain and additional control in all cells
since DAPI’s preference for AT rich regions strongly highlights
chromocenters.
Since MeCP2 plays a crucial role in RTT syndrome one of the
most important goals for us was to test whether the antibodies
work on brain tissue detecting MeCP2 in its native conformation.
We, therefore, prepared cryosections of wild type mouse brain
and also MeCP2 hemizygous null male mouse brain as negative
control. The 25 mm-thick wild type brain sections were stained
with the anti MeCP2 antibodies and counterstained with DAPI as
marker for chromocenters. As demonstrated in Figure 6B our rat
monoclonal antibodies show a strong and specific staining of
chromocenters colocalizing with DAPI. Our mouse monoclonal
antibody 4B4 shows a less intense but still specific staining of
MeCP2. Unfortunately, the antibody 8D11 was not able to detect
endogenous MeCP2 in brain, as it had failed to do with ectopic
MeCP2 expression in cells, and is therefore not suitable for
immunofluorescence. The strongest signals were achieved with
our polyclonal rabbit antiserum, which was used as a positive
control (Figure 6B). To verify the specificity to MeCP2 we
performed the same stainings in MeCP2 null mouse brain
sections. We added anti B23 nucleoli marker antibody as a
positive staining control. As shown in Figure 6C none of the anti
MeCP2 antibodies showed any significant signal in the knock out
brain sections whereas B23 showed a clear and specific signal.
The double staining with anti-B23 mouse monoclonal antibody
was facilitated by the combination with our rat monoclonals,
whereas, in the case of the mouse monoclonals, we had to
perform the anti B23 staining using an adjacent tissue section.
Additionally, using rat monoclonal antibodies obviated the cross
reaction with endogenous mouse immunoglobulins present in the
tissue, whereas these were readily detected when using the mouse
monoclonal antibodies.
X chromosome inactivation skewing in MeCP2
heterozygous mouse brain
Since MeCP2 lies on the X chromosome it is subjected to
random X chromosome inactivation in early development. In
RTT, X chromosome inactivation leads to a mosaic pattern of all
the cells, theoretically in a 50:50 ratio of healthy (active X
containing wild type MeCP2 allele) and affected (active X
containing mutant Mecp2 allele) cells. Deviations from this ratio
indicate skewed inactivation of the X chromosome and affect the
severity of RTT symptoms. Our antibodies should be highly
suitable for studies concerning X chromosome inactivation as well
as other studies on RTT affected brain and other tissues.
To test this, we evaluated X chromosome inactivation skewing
in female MeCP2 heterozygous brain. We performed a double
Figure 7. X chromosome inactivation skewing in brain from heterozygous MeCP2 null mouse. A) Schematic overview of a cryosection of
a (female) heterozygous MeCP2 null brain with regions analyzed for X chromosome inactivation skewing marked with white squares. The results of
the quantification of tyrosine hydroxylase positive, MeCP2 positive or negative cells are shown. N indicates the number of tyrosine hydroxylase
positive neurons scored. B) Representative images of a section co stained with DAPI (DNA), anti MeCP2 (4H7) and anti tyrosine hydroxylase
antibodies. The motor cortex region is depicted in an overview (upper panels; scale bar 80 mm). A magnification corresponding to the red square is
shown in the lower panels (scale bar 20 mm). To illustrate the scoring strategy, an example of tyrosine hydroxylase and MeCP2 positive neuron is
marked by+and of tyrosine hydroxylase positive and MeCP2 negative neuron is marked by -.
doi:10.1371/journal.pone.0026499.g007
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staining with rabbit anti tyrosine hydroxylase (TH) and our rat
MeCP2 antibody (4H7). TH is the first enzyme in the
biosynthesis of dopamine and norepinephrine from tyrosine
and is, therefore, a marker for dopaminergic and noradrenergic
neurons. Roux et al. [29] showed that TH positive cells always
co-expressed MeCP2 and, hence, X chromosome inactivation
skewing can be obtained by counting TH positive cells with and
without MeCP2 signal. We focused on two areas of the cortex,
the motor cortex and the somatosensory cortex (Figure 7). In
both cases we could observe a pronounced X chromosome
inactivation skewing favoring wild type MeCP2 expression
(73%). Previously published mouse data suggest that X
chromosome inactivation skewing in brain is the reason for very
different phenotypes in RTT [30]. The degree of skewing is
controversial and might dependent on the tissue analyzed or the
method applied [30,31]. Our antibodies could help to elucidate
the state of X chromosome inactivation in RTT tissue in
particular also with respect to truncated versus full length
MeCP2 by a combination of the N and C-terminal specific
antibodies.
Figure 8 summarizes the characterization of the novel anti
MeCP2 antibodies. The antibodies recognize MeCP2 from
different species, including human, mouse, rat and pig. Whereas
the two new mouse antibodies are suitable for western blot,
immunoprecipitation and to a lesser extend for immunofluores-
cence, the rabbit polyclonal as well as the rat monoclonal
antibodies performed very well in immunoblotting, immunopre-
cipitation, and immunofluorescence analysis of ectopic and
endogenous MeCP2. In addition, one mouse and two rat
monoclonal antibodies as well as the rabbit polyclonal antiserum
perform well in chromatin immunoprecipitation making them a
very valuable set of tools for studies of MeCP2 pathophysiology in
situ and in vitro.
Supporting Information
Figure S1 A) Epitope mapping. Complete blots of the
epitope mapping presented in Figure 3 together with a schematic
representation of the constructs. B) In situ analysis of MeCP2
in cells. Mouse myoblasts (C2C12 cells) were transiently
transfected with GFP-MECP2 (human) and fixed with methanol.
MECP2 was then detected with our monoclonal antibodies
(undiluted) and our rabbit polyclonal antibody (1:500). The first
row shows the DNA counterstain (DAPI) of transfected and
untransfected cells (green). The row underneath shows the signal
obtained by our antibody staining (red). The third row shows the
localization of the transfected GFP-MECP2 (blue). The merge
contains an overlay of the antibody staining, the fluorescent signal
of GFP-MECP2 and the DNA counterstain. Scale bar 20 mm.
(PDF)
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